Research Laboratories and Vaccines - Pharmacy Technician Pulse

Research Laboratories

Vaccines

FDA Approves Clesrovimab-cfor for Prevention of RSV in Infants

Drug Topics

JUNE 10, 2025

Exclusion criteria included having a bleeding disorder or having received any vaccine or monoclonal antibody for the prevention of RSV. Patients were included if they were a healthy early or moderate pre-term infant or late pre-term or full-term infant.

FDA

FDA Vaccines Adverse Reactions Specialty Pharmacies

FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1

Drug Topics

JULY 10, 2025

“Merck has been at the forefront of HIV research for more than 35 years and we are pleased to continue our work to innovate and deliver new options that aim to meet the needs of the HIV community,” Eliav Barr, senior vice president, head of global clinical development and chief medical officer at Merck Research Laboratories, said in a release.

FDA

FDA Vaccines Specialty Pharmacies Compounding

Join 5,000+

Insiders

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

FDA to review MSD’s doravirine/islatravir NDA for HIV-1

Pharmaceutical Technology

JULY 14, 2025

How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma Formulate Faster.

FDA

FDA Packaging Hospitals Research Laboratories

FDA approves MSD’s Keytruda to treat head and neck cancer

Pharmaceutical Technology

JUNE 16, 2025

GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

FDA

FDA Research Laboratories Communication Hospitals

MSD bolsters US manufacturing capacity with $1b investment

European Pharmaceutical Review

MARCH 12, 2025

MSD has announced it has opened a new $1 billion vaccine manufacturing facility at its site in Durham, North Carolina, US. MSD shared that a further $8 billion of US capital investment is anticipated by 2028.

Research Laboratories

Research Laboratories Vaccines

MSD to advance investigational Lp(a) inhibitor in nearly $2b deal

European Pharmaceutical Review

MARCH 25, 2025

Expanding treatment options for atherosclerosis with an Lp(a) inhibitor “The drug is an important addition that expands and complements our cardio-metabolic pipeline, remarked Dr Dean Li, President, Merck Research Laboratories.

Research Laboratories

Research Laboratories Vaccines

Merck and Moderna partner to develop and sell cancer vaccine

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018.

Vaccines

Vaccines Research Laboratories Immunization

US FDA grants approval for Merck’s pneumococcal vaccine for children

Pharmaceutical Technology

JUNE 23, 2022

The US Food and Drug Administration (FDA) has granted approval for Merck's (MSD outside the US and Canada) pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for use in children aged six weeks to 17 years. The post US FDA grants approval for Merck’s pneumococcal vaccine for children appeared first on Pharmaceutical Technology.

Vaccines

Vaccines FDA Research Laboratories Immunization

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

AUGUST 17, 2022

These programmes will include therapies and vaccines in infectious disease and oncology areas. Preclinical data showed the potential of oRNA expression and delivery as a method for advanced development in various areas, including vaccines and oncology treatments. Topic sponsors are not involved in the creation of editorial content.

Vaccines

Vaccines Research Laboratories Packaging

Positive results for mRNA vaccine in melanoma patients

European Pharmaceutical Review

DECEMBER 15, 2023

Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. The post Positive results for mRNA vaccine in melanoma patients appeared first on European Pharmaceutical Review.

Vaccines

Vaccines Research Laboratories Immunization

Merck and Orion enter partnership to develop ODM-208 for prostate cancer

Pharmaceutical Technology

JULY 13, 2022

Merck Research Laboratories president Dr Dean Li said: “Targeting CYP11A1 provides a compelling approach to suppressing the production of steroid hormones, a key driver of prostate cancer. “We The latest deal complements and bolsters the oncology pipeline of Merck.

Research Laboratories

Research Laboratories Vaccines

Pharmaceutical microbiology: key developments 2022

European Pharmaceutical Review

JANUARY 16, 2023

The safety and efficacy of mRNA vaccines should be a game changer and is the likely solution to antibiotic-resistant microorganisms and emerging viral pathogens.” The previous record for vaccine development and approval was four years for the measles vaccine. Perhaps we will see a universal flu vaccine in the near future.

Vaccines

Vaccines FDA Research Laboratories Documentation

Merck to support development of Orna’s circular RNA (oRNA) therapies

European Pharmaceutical Review

AUGUST 18, 2022

Merck (MSD outside of the US and Canada) has entered into a collaboration agreement with Orna Therapeutics to discover, develop and commercialise multiple programmes of engineered circular RNA (oRNA) therapies, including vaccines and therapeutics in the areas of infectious disease and oncology.

Research Laboratories

Research Laboratories Vaccines Packaging

European Pharmaceutical Review Issue 3 2024

European Pharmaceutical Review

JUNE 28, 2024

Taly Dvorkis Fieldfisher QA/QC MICROBIOLOGY IN DEPTH FOCUS Implementing single temperature incubation Guillaume Pinon Laboratoires SERVIER Industrie Endotoxin standards: reflection and recommendation Dr Radhakrishna Tirumalai Merck Research Laboratories (MRL) Karen Zink McCullough MMI Associates, LLC Improving aseptic connections throughout the manufacturing (..)

Research Laboratories

Research Laboratories Vaccines Immunization

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Pharmaceutical Technology

FEBRUARY 20, 2023

The formal signing ceremony of the MoU today at Cerba Research’s Ghent office was led by Mario Papillon, CEO of Cerba Research, and Xu Yi, CEO of Teddy Lab, on behalf of their respective organisations. I am proud and humble to say that, together, Cerba Research and Teddy Lab have contributed greatly to the fight against the pandemic.

Research Laboratories

Research Laboratories Vaccines Pharmaceutical Companies Pharmaceutical Companies

FDA Approves Clesrovimab-cfor for Prevention of RSV in Infants

FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1

Trending Sources

FDA to review MSD’s doravirine/islatravir NDA for HIV-1

FDA approves MSD’s Keytruda to treat head and neck cancer

MSD bolsters US manufacturing capacity with $1b investment

MSD to advance investigational Lp(a) inhibitor in nearly $2b deal

Merck and Moderna partner to develop and sell cancer vaccine

US FDA grants approval for Merck’s pneumococcal vaccine for children

Merck and Orna partner for RNA technology-based vaccines and therapies

Positive results for mRNA vaccine in melanoma patients

Merck and Orion enter partnership to develop ODM-208 for prostate cancer

Pharmaceutical microbiology: key developments 2022

Merck to support development of Orna’s circular RNA (oRNA) therapies

European Pharmaceutical Review Issue 3 2024

Cerba Research and Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture

Stay Connected